Study of upadacitinib for eczema after dupilumab didn't work
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema for at least 3 years.
- Your eczema is moderate to severe (a doctor will measure this with scores like EASI, vIGA-AD, and body surface area).
- You have been using dupilumab for at least 4 months but it hasn't worked well enough.
- You have been using a plain moisturizer (emollient) twice daily for at least 7 days before the study starts.
- You do not have other active skin infections, a history of certain serious infections (like shingles, herpes, TB, HIV, hepatitis), or recent major health events (like heart attack, stroke, or blood clots).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.